Rare Pharma Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
- Paid Up Capital ₹ 0.95 M
- Company Age 35 Year, 1 Month
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 6.89 M
- Satisfied Charges ₹ 1.15 Cr
- Revenue Growth 1694.85%
- Profit Growth -60.09%
- Ebitda 46.23%
- Net Worth -141.60%
- Total Assets -22.00%
About Rare Pharma
Rare Pharma Private Limited (RPPL) is a Private Limited Indian Non-Government Company incorporated in India on 28 December 1989 and has a history of 35 years and one month. Its registered office is in Thane, Maharashtra, India.
The Company is engaged in the Chemicals And Materials Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.95 M.
The company currently has active open charges totaling ₹6.89 M. The company has closed loans amounting to ₹1.15 Cr, as per Ministry of Corporate Affairs (MCA) records.
Rajendra Pawar, Pramila Pawar, and Chandrasen Shinde serve as directors at the Company.
Company Details
-
Location
Thane, Maharashtra, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
Social Media-
Corporate Identity Details
-
CIN/LLPIN
U99999MH1989PTC054794
-
Company No.
054794
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
28 Dec 1989
-
Date of AGM
30 Sep 2023
-
Date of Balance Sheet
31 Mar 2023
-
Listing Status
Unlisted
-
ROC Code
Roc Mumbai
Industry
Who are the key members and board of directors at Rare Pharma?
Board Members (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Rajendra Pawar
|
Director | 21-Oct-2019 | Current |
|
Pramila Pawar
|
Director | 21-Oct-2019 | Current |
|
Chandrasen Shinde
|
Director | 22-May-2023 | Current |
Financial Performance of Rare Pharma.
Rare Pharma Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 1694.85% increase. The company also saw a substantial fall in profitability, with a 60.09% decrease in profit. The company's net worth observed a substantial decline by a decrease of 141.6%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Rare Pharma?
Unlock access to Rare Pharma's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Related Corporates (Common Directorship)
-
_PRIVATE_LIMITED.webp)
Samuh-Laxmi Chemicals (Bombay) Private LimitedRajendra Pawar and Pramila Pawar are mutual person
-
Badlapur Common Effluent Treatment Plant AssociationChandrasen Shinde is a mutual person
Charges (Loans)
₹6.89 M
₹11.45 M
Charges Breakdown by Lending Institutions
- Yes Bank Limited : 0.69 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 08 Dec 2022 | Yes Bank Limited | ₹6.89 M | Open |
| 13 Oct 2007 | Janakalyan Sahakari Bank Limited | ₹0.20 M | Satisfied |
| 13 Oct 2007 | Janakalyan Sahakari Bank Limited | ₹2.70 M | Satisfied |
| 13 Oct 2007 | Janakalyan Sahakari Bank Limited | ₹0.70 M | Satisfied |
| 18 Mar 2002 | Janakalyan Sahakari Bank Ltd | ₹4.20 M | Satisfied |
How Many Employees Work at Rare Pharma?
Unlock and access historical data on people associated with Rare Pharma, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Rare Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Rare Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
